20-F 1 zepp-20221231x20f.htm FORM 20-F
http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities00017204462022FYfalseP4YP4YP4Y1173740009097000http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilitiesP1Y0.1200017204462019-04-012019-04-0100017204462018-05-012018-05-0100017204462018-04-302018-04-300001720446srt:MinimumMemberzepp:CooperationAgreementMember2022-01-012022-12-310001720446srt:MaximumMemberzepp:CooperationAgreementMember2022-01-012022-12-310001720446country:CN2022-12-310001720446us-gaap:EmployeeStockOptionMemberzepp:EquityIncentivePlanTwoThousandEighteenMember2018-01-012018-01-010001720446srt:MinimumMemberus-gaap:CanadaRevenueAgencyMember2022-01-012022-12-310001720446srt:MaximumMemberus-gaap:CanadaRevenueAgencyMember2022-01-012022-12-310001720446us-gaap:InternalRevenueServiceIRSMember2017-01-012017-12-310001720446us-gaap:InlandRevenueHongKongMember2022-01-012022-12-310001720446us-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001720446us-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001720446zepp:AnhuiHuamiAnhuiHealthAndShunYuanMember2022-01-012022-12-310001720446zepp:AnhuiHuamiAnhuiHealthAndShunYuanMember2021-01-012021-12-310001720446zepp:AnhuiHuamiAnhuiHealthAndShunYuanMember2020-01-012020-12-310001720446zepp:PaiAcquisitionMember2022-01-012022-12-310001720446zepp:PaiAcquisitionMember2021-01-012021-12-310001720446zepp:JiangsuYitongHighTechCoLtdMember2021-02-280001720446zepp:InvestmentInPromaxoMember2020-12-310001720446zepp:InvestmentInAlivoreMember2020-02-290001720446zepp:SifiveIncMember2018-12-310001720446us-gaap:OtherIntangibleAssetsMemberzepp:JiangsuYitongHighTechCoLtdMember2022-12-310001720446us-gaap:OtherAssetsMemberzepp:JiangsuYitongHighTechCoLtdMember2022-12-310001720446us-gaap:GoodwillMemberzepp:JiangsuYitongHighTechCoLtdMember2022-12-310001720446us-gaap:OtherIntangibleAssetsMemberzepp:JiangsuYitongHighTechCoLtdMember2021-12-310001720446us-gaap:OtherAssetsMemberzepp:JiangsuYitongHighTechCoLtdMember2021-12-310001720446us-gaap:GoodwillMemberzepp:JiangsuYitongHighTechCoLtdMember2021-12-310001720446zepp:YundingMember2020-12-012020-12-310001720446zepp:AcquisitionOfGuoxuInsuranceBrokerageCo.LtdMember2020-07-310001720446us-gaap:MajorityShareholderMember2022-01-012022-12-310001720446srt:MinimumMember2022-12-310001720446us-gaap:TreasuryStockCommonMember2022-12-310001720446us-gaap:TreasuryStockCommonMember2021-12-310001720446us-gaap:TreasuryStockCommonMember2019-12-310001720446us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-12-012021-12-310001720446us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-01-012022-12-310001720446us-gaap:TreasuryStockCommonMember2022-01-012022-12-310001720446us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-01-012021-12-310001720446us-gaap:TreasuryStockCommonMember2021-01-012021-12-310001720446us-gaap:CommonStockMember2022-01-012022-12-310001720446us-gaap:CommonStockMember2021-01-012021-12-310001720446us-gaap:CommonStockMember2020-01-012020-12-310001720446us-gaap:RetainedEarningsMember2022-12-310001720446us-gaap:ParentMember2022-12-310001720446us-gaap:NoncontrollingInterestMember2022-12-310001720446us-gaap:AdditionalPaidInCapitalMember2022-12-310001720446us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001720446us-gaap:RetainedEarningsMember2021-12-310001720446us-gaap:ParentMember2021-12-310001720446us-gaap:NoncontrollingInterestMember2021-12-310001720446us-gaap:AdditionalPaidInCapitalMember2021-12-310001720446us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001720446us-gaap:RetainedEarningsMember2020-12-310001720446us-gaap:ParentMember2020-12-310001720446us-gaap:AdditionalPaidInCapitalMember2020-12-310001720446us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001720446us-gaap:RetainedEarningsMember2019-12-310001720446us-gaap:ParentMember2019-12-310001720446us-gaap:NoncontrollingInterestMember2019-12-310001720446us-gaap:AdditionalPaidInCapitalMember2019-12-310001720446us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001720446zepp:JiangsuYitongHighTechCoLtdMember2022-12-310001720446us-gaap:CommonStockMember2022-12-310001720446us-gaap:CommonStockMember2021-12-310001720446us-gaap:CommonStockMember2020-12-310001720446us-gaap:CommonStockMember2019-12-310001720446srt:WeightedAverageMemberus-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-12-310001720446srt:WeightedAverageMemberus-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-12-310001720446srt:MinimumMemberus-gaap:EmployeeStockOptionMember2021-12-310001720446srt:MaximumMemberus-gaap:EmployeeStockOptionMember2021-12-310001720446srt:MinimumMemberus-gaap:EmployeeStockOptionMember2020-12-310001720446srt:MaximumMemberus-gaap:EmployeeStockOptionMember2020-12-310001720446us-gaap:EmployeeStockOptionMemberzepp:EquityIncentivePlanTwoThousandFifteenAndEquityIncentivePlanTwoThousandEighteenMember2021-12-310001720446us-gaap:EmployeeStockOptionMemberzepp:PeopleRepublicOfChinaServiceProvidersEquityIncentivePlanMember2022-01-012022-12-310001720446us-gaap:EmployeeStockOptionMemberzepp:PeopleRepublicOfChinaServiceProvidersEquityIncentivePlanMember2021-01-012021-12-310001720446us-gaap:EmployeeStockOptionMemberzepp:PeopleRepublicOfChinaServiceProvidersEquityIncentivePlanMember2020-01-012020-12-310001720446us-gaap:EmployeeStockOptionMemberzepp:EquityIncentivePlanTwoThousandFifteenAndEquityIncentivePlanTwoThousandEighteenMember2022-01-012022-12-310001720446us-gaap:EmployeeStockOptionMemberzepp:EquityIncentivePlanTwoThousandFifteenAndEquityIncentivePlanTwoThousandEighteenMember2022-12-310001720446zepp:ShareIncentivePlan2023Memberus-gaap:SubsequentEventMember2023-01-110001720446us-gaap:EmployeeStockOptionMemberzepp:EquityIncentivePlanTwoThousandEighteenMember2018-01-010001720446zepp:EquityIncentivePlanTwoThousandFifteenMember2015-10-210001720446us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001720446us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001720446us-gaap:EmployeeStockOptionMember2020-01-012020-12-310001720446us-gaap:RestrictedStockUnitsRSUMember2021-12-310001720446us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-01-012022-12-310001720446srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001720446srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001720446us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2021-01-012021-12-310001720446srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001720446srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001720446us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2020-01-012020-12-310001720446srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001720446srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001720446zepp:RelatedPartyConcentrationRiskMember2022-01-012022-12-310001720446us-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001720446us-gaap:CreditConcentrationRiskMember2022-01-012022-12-310001720446zepp:XiaomiYoupinMember2022-01-012022-12-310001720446zepp:XiaomiCommunicationTechnologyCompanyLimitedMember2022-01-012022-12-310001720446zepp:XiaomiYoupinMember2021-01-012021-12-310001720446zepp:XiaomiCommunicationTechnologyCompanyLimitedMember2021-01-012021-12-310001720446zepp:XiaomiCommunicationTechnologyCompanyLimitedMember2020-01-012020-12-310001720446zepp:HefeiJingyuMicroElectronicsMember2022-01-012022-12-310001720446zepp:HefeiJingyuMicroElectronicsMember2021-01-012021-12-310001720446zepp:OtherRelatedPartiesMember2020-01-012020-12-310001720446srt:MinimumMemberus-gaap:ComputerEquipmentMember2022-01-012022-12-310001720446srt:MaximumMemberus-gaap:ComputerEquipmentMember2022-01-012022-12-310001720446us-gaap:BuildingMember2022-01-012022-12-310001720446us-gaap:LeaseholdImprovementsMember2022-12-310001720446us-gaap:ConstructionInProgressMember2022-12-310001720446us-gaap:ComputerEquipmentMember2022-12-310001720446us-gaap:BuildingMember2022-12-310001720446us-gaap:LeaseholdImprovementsMember2021-12-310001720446us-gaap:ConstructionInProgressMember2021-12-310001720446us-gaap:ComputerEquipmentMember2021-12-310001720446us-gaap:BuildingMember2021-12-310001720446us-gaap:NoncontrollingInterestMember2022-01-012022-12-310001720446us-gaap:RetainedEarningsMember2021-01-012021-12-310001720446us-gaap:NoncontrollingInterestMember2021-01-012021-12-310001720446us-gaap:RetainedEarningsMember2020-01-012020-12-310001720446us-gaap:CostOfSalesMember2022-01-012022-12-310001720446us-gaap:CostOfSalesMember2021-01-012021-12-310001720446us-gaap:CostOfSalesMember2020-01-012020-12-310001720446zepp:YundingMember2021-01-012021-01-310001720446zepp:HuayingFundIiMember2021-03-012021-03-310001720446zepp:JiangsuYitongHighTechCoLtdMember2021-02-012021-02-280001720446zepp:ShenzhenYundingInformationTechnologyCompanyLimitedMember2020-01-012020-12-310001720446zepp:InvestmentInAlivoreMember2019-01-012019-12-310001720446zepp:HuayingFundIiMember2019-01-012019-12-310001720446zepp:SifiveIncMember2018-01-012018-12-310001720446zepp:HuayingFundMember2016-01-012016-12-310001720446zepp:OtherInvestorsMember2022-01-012022-12-310001720446zepp:OtherInvestorsMember2021-01-012021-12-310001720446zepp:OtherInvestorsMember2020-01-012020-12-310001720446us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberzepp:ShenzhenYundingInformationTechnologyCompanyLimitedMember2022-01-012022-12-310001720446us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberzepp:ShenzhenYundingInformationTechnologyCompanyLimitedMember2020-01-012020-12-310001720446us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001720446us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001720446us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310001720446zepp:PeopleOfRepublicChinaHongKongUnitedStatesAndCanadaMember2022-01-012022-12-310001720446us-gaap:NoncontrollingInterestMember2020-01-012020-12-310001720446us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-01-012022-12-310001720446us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-01-012021-12-310001720446us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2020-01-012020-12-310001720446us-gaap:VariableInterestEntityPrimaryBeneficiaryMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2022-01-012022-12-310001720446us-gaap:VariableInterestEntityPrimaryBeneficiaryMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2021-01-012021-12-310001720446us-gaap:VariableInterestEntityPrimaryBeneficiaryMembersrt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember2020-01-012020-12-310001720446zepp:ZeppNorthAmericaInc.Member2022-12-310001720446zepp:ZeppNetherlandsTradingB.v.Member2022-12-310001720446zepp:ZeppIncMember2022-12-310001720446zepp:ZeppEuropeHoldingB.v.Member2022-12-310001720446zepp:HuamiShenzhenInformationTechnologyCompanyLimitedMember2022-12-310001720446zepp:HongKongZeppHoldingLimitedMember2022-12-310001720446zepp:GalaxyTradingPlatformLimited.Member2022-12-310001720446zepp:BeijingShunYuanKaiHuaTechnologyCompanyLimitedMember2022-12-310001720446zepp:AnhuiHuamiIntelligentTechnologyCompanyLimitedMember2022-12-310001720446zepp:HuamiBeijingInformationTechnologyCompanyLimitedMember2017-11-030001720446zepp:AnhuiHuamiInformationTechnologyCoLtdMember2015-04-290001720446us-gaap:RedeemablePreferredStockMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001720446us-gaap:RedeemablePreferredStockMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001720446us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BondsMember2022-12-310001720446us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2022-12-310001720446us-gaap:RedeemablePreferredStockMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001720446us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2022-12-310001720446us-gaap:FairValueMeasurementsRecurringMemberus-gaap:BondsMember2022-12-310001720446us-gaap:RedeemablePreferredStockMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001720446us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2021-12-310001720446us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:BondsMember2021-12-310001720446us-gaap:RedeemablePreferredStockMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001720446us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2021-12-310001720446us-gaap:FairValueMeasurementsRecurringMemberus-gaap:BondsMember2021-12-310001720446us-gaap:EquityMethodInvestmentsMember2022-12-310001720446us-gaap:EquityMethodInvestmentsMember2021-12-310001720446srt:MinimumMemberzepp:ShenzhenYundingInformationTechnologyCompanyLimitedMember2020-12-310001720446srt:MaximumMemberzepp:ShenzhenYundingInformationTechnologyCompanyLimitedMember2020-12-310001720446us-gaap:LicensingAgreementsMember2022-12-310001720446us-gaap:InternetDomainNamesMember2022-12-310001720446us-gaap:LicensingAgreementsMember2021-12-310001720446us-gaap:InternetDomainNamesMember2021-12-310001720446zepp:JiangsuYitongHighTechCoLtdMember2022-01-012022-12-310001720446zepp:HuayingFundMember2022-01-012022-12-310001720446zepp:HuayingFundIiMember2022-01-012022-12-310001720446zepp:JiangsuYitongHighTechCoLtdMember2021-01-012021-12-310001720446zepp:HuayingFundMember2021-01-012021-12-310001720446zepp:HuayingFundIiMember2021-01-012021-12-310001720446zepp:HuayingFundMember2020-01-012020-12-310001720446zepp:HuayingFundIiMember2020-01-012020-12-310001720446us-gaap:EquityMethodInvestmentsMember2022-01-012022-12-310001720446us-gaap:EquityMethodInvestmentsMember2021-01-012021-12-310001720446us-gaap:EquityMethodInvestmentsMember2020-01-012020-12-310001720446us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberzepp:ShenzhenYundingInformationTechnologyCompanyLimitedMember2021-01-012021-12-310001720446srt:MinimumMemberus-gaap:TradeDressMember2022-01-012022-12-310001720446srt:MaximumMemberus-gaap:TradeDressMember2022-01-012022-12-310001720446us-gaap:RedeemablePreferredStockMember2022-12-310001720446us-gaap:RedeemablePreferredStockMember2021-12-310001720446us-gaap:RedeemablePreferredStockMember2020-12-310001720446us-gaap:RedeemablePreferredStockMember2022-01-012022-12-310001720446us-gaap:RedeemablePreferredStockMember2021-01-012021-12-310001720446zepp:SifiveIncMember2022-12-310001720446zepp:PromaxoIncMember2022-12-310001720446zepp:AlivecorIncMember2022-12-310001720446zepp:SifiveIncMember2021-12-310001720446zepp:PromaxoIncMember2021-12-310001720446zepp:AlivecorIncMember2021-12-310001720446zepp:InvestmentInPromaxoMember2022-01-012022-12-310001720446zepp:InvestmentInPromaxoMember2021-01-012021-12-310001720446zepp:InvestmentInPromaxoMember2020-01-012020-12-310001720446zepp:SifiveIncMember2022-12-310001720446zepp:InvestmentInHyperfineMember2022-12-310001720446zepp:InvestmentInAlivoreMember2022-12-310001720446zepp:HyperfineResearchIncMember2022-12-310001720446zepp:SifiveIncMember2021-12-310001720446zepp:InvestmentInHyperfineMember2021-12-310001720446zepp:InvestmentInAlivoreMember2021-12-310001720446zepp:HyperfineResearchIncMember2021-12-310001720446zepp:SifiveIncMember2020-12-310001720446zepp:InvestmentInAlivoreMember2020-12-310001720446zepp:OthersMember2022-12-310001720446zepp:JiangsuYitongHighTechCoLtdMember2022-12-310001720446zepp:HuayingFundMember2022-12-310001720446zepp:HuayingFundIiMember2022-12-310001720446zepp:OthersMember2021-12-310001720446zepp:HuayingFundMember2021-12-310001720446zepp:HuayingFundIiMember2021-12-310001720446zepp:ShenzhenYundingInformationTechnologyCompanyLimitedMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberzepp:ShenzhenYundingInformationTechnologyCompanyLimitedMember2022-12-310001720446zepp:HuayingFundIiMemberzepp:HuayingFundIiMember2019-12-310001720446zepp:HuayingFundIiMemberzepp:HuayingFundMember2016-12-310001720446us-gaap:EmployeeStockOptionMember2022-12-310001720446us-gaap:RestrictedStockUnitsRSUMember2022-12-310001720446zepp:AnhuiHuamiIntelligentTechnologyCompanyLimitedMemberus-gaap:StateAdministrationOfTaxationChinaMember2022-01-012022-12-310001720446zepp:AnhuiHuamiInformationTechnologyCoLtdMemberus-gaap:StateAdministrationOfTaxationChinaMember2022-01-012022-12-310001720446zepp:BeijingShunyuanMember2022-01-012022-12-310001720446us-gaap:TaxAndCustomsAdministrationNetherlandsMember2022-01-012022-12-310001720446us-gaap:StateAdministrationOfTaxationChinaMember2022-01-012022-12-310001720446us-gaap:InternalRevenueServiceIRSMember2022-01-012022-12-310001720446zepp:AnhuiHuamiIntelligentTechnologyCompanyLimitedMemberus-gaap:StateAdministrationOfTaxationChinaMember2021-01-012021-12-310001720446zepp:AnhuiHuamiInformationTechnologyCoLtdMemberus-gaap:StateAdministrationOfTaxationChinaMember2021-01-012021-12-310001720446zepp:AnhuiHuamiIntelligentTechnologyCompanyLimitedMemberus-gaap:StateAdministrationOfTaxationChinaMember2020-01-012020-12-310001720446zepp:AnhuiHuamiInformationTechnologyCoLtdMemberus-gaap:StateAdministrationOfTaxationChinaMember2020-01-012020-12-310001720446srt:MinimumMemberus-gaap:InlandRevenueHongKongMember2018-04-012018-04-010001720446srt:MaximumMemberus-gaap:InlandRevenueHongKongMember2018-04-012018-04-010001720446zepp:XiaomiTechnologyCompanyLimitedMember2022-12-310001720446zepp:XiaomiTechnologyCompanyLimitedMember2021-12-310001720446srt:VicePresidentMember2022-12-310001720446zepp:RelatedPartyConcentrationRiskMemberus-gaap:CreditConcentrationRiskMemberzepp:MajorCustomersMember2022-12-310001720446zepp:RelatedPartyConcentrationRiskMemberus-gaap:CreditConcentrationRiskMemberzepp:CompanyCMember2022-12-310001720446zepp:XiaomiCommunicationTechnologyCompanyLimitedMember2022-12-310001720446zepp:ShenzhenYundingInformationTechnologyCompanyLimitedMember2022-12-310001720446zepp:OtherRelatedPartiesMember2022-12-310001720446zepp:HefeiZeppMedicalSystemCo.LtdMember2022-12-310001720446zepp:HefeiLianruiMicroelectronicsTechnologyCo.LtdMember2022-12-310001720446zepp:HefeiJingyuMicroElectronicsMember2022-12-310001720446zepp:GongqingchengYundingMember2022-12-310001720446zepp:RelatedPartyConcentrationRiskMemberus-gaap:CreditConcentrationRiskMemberzepp:MajorCustomersMember2021-12-310001720446zepp:RelatedPartyConcentrationRiskMemberus-gaap:CreditConcentrationRiskMemberzepp:CompanyCMember2021-12-310001720446zepp:XiaomiCommunicationTechnologyCompanyLimitedMember2021-12-310001720446zepp:ShenzhenYundingInformationTechnologyCompanyLimitedMember2021-12-310001720446zepp:OtherRelatedPartiesMember2021-12-310001720446zepp:HefeiLianruiMicroelectronicsTechnologyCo.LtdMember2021-12-310001720446zepp:HefeiJingyuMicroElectronicsMember2021-12-310001720446zepp:GongqingchengYundingMember2021-12-310001720446dei:AdrMember2022-03-1700017204462022-03-170001720446us-gaap:RetainedEarningsMember2022-01-012022-12-310001720446us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberzepp:ShenzhenYundingInformationTechnologyCompanyLimitedMember2021-12-310001720446us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberzepp:ShenzhenYundingInformationTechnologyCompanyLimitedMember2020-12-310001720446zepp:YundingMember2020-12-310001720446zepp:ShenzhenYundingInformationTechnologyCompanyLimitedMember2020-01-012020-12-310001720446srt:MinimumMember2022-01-012022-12-310001720446srt:MaximumMember2022-01-012022-12-310001720446zepp:InvestmentInAlivoreMember2019-12-310001720446us-gaap:ProductMember2022-01-012022-12-310001720446us-gaap:ManufacturedProductOtherMember2022-01-012022-12-310001720446us-gaap:ProductMember2021-01-012021-12-310001720446us-gaap:ManufacturedProductOtherMember2021-01-012021-12-310001720446us-gaap:ProductMember2020-01-012020-12-310001720446us-gaap:ManufacturedProductOtherMember2020-01-012020-12-310001720446zepp:RelatedPartyConcentrationRiskMemberus-gaap:CreditConcentrationRiskMemberzepp:MajorCustomersMember2022-01-012022-12-310001720446zepp:RelatedPartyConcentrationRiskMemberus-gaap:CreditConcentrationRiskMemberzepp:CompanyCMember2022-01-012022-12-310001720446zepp:MajorCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001720446zepp:ExclusivelyDesignedAndManufacturedSmartWearableDevicesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001720446zepp:CompanyBMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001720446zepp:CompanyAMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001720446us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberzepp:MajorCustomersMember2022-01-012022-12-310001720446us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberzepp:CompanyCMember2022-01-012022-12-310001720446zepp:RelatedPartyConcentrationRiskMemberus-gaap:CreditConcentrationRiskMemberzepp:MajorCustomersMember2021-01-012021-12-310001720446zepp:RelatedPartyConcentrationRiskMemberus-gaap:CreditConcentrationRiskMemberzepp:CompanyCMember2021-01-012021-12-310001720446zepp:MajorCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001720446zepp:ExclusivelyDesignedAndManufacturedSmartWearableDevicesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001720446zepp:CompanyBMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001720446zepp:CompanyAMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001720446us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberzepp:MajorCustomersMember2021-01-012021-12-310001720446us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberzepp:CompanyCMember2021-01-012021-12-310001720446zepp:ExclusivelyDesignedAndManufacturedSmartWearableDevicesMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001720446us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberzepp:MajorCustomersMember2020-01-012020-12-310001720446us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberzepp:CompanyCMember2020-01-012020-12-310001720446us-gaap:CostOfGoodsProductLineMemberus-gaap:SupplierConcentrationRiskMemberzepp:CustomerDMember2020-01-012020-12-310001720446us-gaap:CommonClassBMember2021-12-310001720446us-gaap:CommonClassAMember2021-12-3100017204462019-12-310001720446currency:USD2022-12-310001720446currency:CNY2022-12-310001720446currency:USD2021-12-310001720446currency:CNY2021-12-310001720446zepp:PaiAcquisitionMember2020-06-122020-06-120001720446zepp:PaiAcquisitionMember2020-06-120001720446zepp:CooperationAgreementMember2022-12-310001720446zepp:CooperationAgreementMember2021-12-310001720446zepp:CooperationAgreementMember2020-12-310001720446zepp:YundingMember2022-12-310001720446zepp:OthersMember2022-12-310001720446zepp:YundingMember2021-12-310001720446zepp:OthersMember2021-12-310001720446us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001720446us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001720446us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001720446us-gaap:FairValueMeasurementsRecurringMember2022-12-310001720446us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001720446us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001720446us-gaap:FairValueMeasurementsRecurringMember2021-12-310001720446zepp:JiangsuYitongHighTechCoLtdMember2021-12-310001720446zepp:AcquisitionOfGuoxuInsuranceBrokerageCo.LtdMember2020-07-012020-07-310001720446us-gaap:StockCompensationPlanMember2022-01-012022-12-310001720446us-gaap:StockCompensationPlanMember2021-01-012021-12-310001720446us-gaap:StockCompensationPlanMember2020-01-012020-12-3100017204462020-12-310001720446us-gaap:EmployeeStockOptionMemberzepp:EquityIncentivePlanTwoThousandEighteenMember2022-01-012022-12-310001720446us-gaap:SellingAndMarketingExpenseMember2022-01-012022-12-310001720446us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001720446us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310001720446us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-12-310001720446us-gaap:EmployeeStockOptionMemberzepp:EquityIncentivePlanTwoThousandEighteenMember2021-01-012021-12-310001720446us-gaap:SellingAndMarketingExpenseMember2021-01-012021-12-310001720446us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001720446us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310001720446us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-12-310001720446us-gaap:EmployeeStockOptionMemberzepp:EquityIncentivePlanTwoThousandEighteenMember2020-01-012020-12-310001720446us-gaap:SellingAndMarketingExpenseMember2020-01-012020-12-310001720446us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001720446us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310001720446us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-12-310001720446us-gaap:ParentMember2022-01-012022-12-310001720446us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001720446us-gaap:ParentMember2021-01-012021-12-310001720446us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-3100017204462021-01-012021-12-310001720446us-gaap:ParentMember2020-01-012020-12-310001720446us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-3100017204462020-01-012020-12-310001720446srt:MinimumMemberus-gaap:PatentsMember2022-01-012022-12-310001720446srt:MaximumMemberus-gaap:PatentsMember2022-01-012022-12-310001720446zepp:XiaomiCommunicationInformationTechnologyMember2022-12-310001720446zepp:XiaomiCommunicationInformationTechnologyMember2021-12-310001720446zepp:MajorCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-12-310001720446zepp:CompanyBMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-12-310001720446zepp:CompanyAMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-12-310001720446zepp:MajorCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-12-310001720446zepp:CompanyBMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-12-310001720446zepp:CompanyAMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-12-310001720446us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-12-3100017204462022-12-310001720446us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-12-3100017204462021-12-310001720446zepp:ZeppNorthAmericaInc.Member2022-01-012022-12-310001720446zepp:ZeppNetherlandsTradingB.v.Member2022-01-012022-12-310001720446zepp:ZeppIncMember2022-01-012022-12-310001720446zepp:ZeppEuropeHoldingB.v.Member2022-01-012022-12-310001720446zepp:HuamiShenzhenInformationTechnologyCompanyLimitedMember2022-01-012022-12-310001720446zepp:HuamiBeijingInformationTechnologyCompanyLimitedMember2022-01-012022-12-310001720446zepp:HongKongZeppHoldingLimitedMember2022-01-012022-12-310001720446zepp:GalaxyTradingPlatformLimited.Member2022-01-012022-12-310001720446zepp:BeijingShunYuanKaiHuaTechnologyCompanyLimitedMember2022-01-012022-12-310001720446zepp:AnhuiHuamiIntelligentTechnologyCompanyLimitedMember2022-01-012022-12-310001720446zepp:AnhuiHuamiInformationTechnologyCoLtdMember2022-01-012022-12-310001720446zepp:AnhuiHuamiHealthcareCompanyLimitedMember2022-01-012022-12-310001720446us-gaap:CommonClassBMember2022-12-310001720446us-gaap:CommonClassAMember2022-12-310001720446dei:BusinessContactMember2022-01-012022-12-3100017204462022-01-012022-12-31zepp:itemzepp:installmentxbrli:sharesiso4217:CNYiso4217:USDxbrli:pureiso4217:USDxbrli:sharesiso4217:CNYxbrli:sharesiso4217:USDiso4217:CNYzepp:segmentzepp:customer

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 20-F

(Mark One)

REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2022.

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of event requiring this shell company report.………………………………

For the transition period from                      to                    

Commission file number: 001-38369

ZEPP HEALTH CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

N/A

(Translation of Registrant’s Name Into English)

Cayman Islands

(Jurisdiction of Incorporation or Organization)

Huami Global Innovation Center

Building B2, Zhong’an Chuanggu Technology Park

No. 900 Wangjiang West Road

Hefei, 230088

People’s Republic of China

(Address of Principal Executive Offices)

Leon Cheng Deng, Chief Financial Officer

Huami Global Innovation Center

Building B2, Zhong’an Chuanggu Technology Park

No. 900 Wangjiang West Road

Hefei, 230088

People’s Republic of China

Phone: +86 010 5940 3251

Email: ir@zepp.com

(Name, Telephone, Email and/or Facsimile number and Address of Company Contact Person)

Securities registered or to be registered pursuant to Section 12(b) of the Act:

Title of Each Class

    

Trading Symbol(s)

    

Name of Each Exchange On Which Registered

American depositary shares (each representing four Class A ordinary shares, par value US$0.0001 per share)

Class A ordinary shares, par value US$0.0001 per shares*

ZEPP

 

New York Stock Exchange

*Not for trading, but only in connection with the listing of the American depositary shares on the New York Stock Exchange.

Securities registered or to be registered pursuant to Section 12(g) of the Act:

None

(Title of Class)

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:

None

(Title of Class)

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report:

As of December 31, 2022, there were (i) 128,130,440 Class A ordinary shares issued and outstanding, par value US$0.0001 per share (excluding the 5,616,956 Class A ordinary shares issued to the depositary bank for bulk issuance of ADSs reserved for future issuances upon the exercise or vesting of awards granted under the 2015 Share Incentive Plan, the 2018 Share Incentive Plan and the 2023 Share Incentive Plan and the 12,875,736 treasury shares in the form of ADSs that we repurchased under our share repurchase program), and (ii) 117,208,247 Class B ordinary shares issued and outstanding, par value US$0.0001 per share.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.   Yes     No

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.   Yes     No

Note - Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes     No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes     No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer 

Emerging growth company

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act.

†The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S. GAAP

International Financial Reporting Standards as issued by the

International Accounting Standards Board ☐

Other

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.   Item 17     Item 18

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes     No

(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS)

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.   Yes     No

TABLE OF CONTENTS

INTRODUCTION

1

 

 

FORWARD-LOOKING STATEMENTS

2

 

 

PART I

3

 

 

 

ITEM 1.

IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

3

ITEM 2.

OFFER STATISTICS AND EXPECTED TIMETABLE

3

ITEM 3.

KEY INFORMATION

3

ITEM 4.

INFORMATION ON THE COMPANY

61

ITEM 4A.

UNRESOLVED STAFF COMMENTS

92

ITEM 5.

OPERATING AND FINANCIAL REVIEW AND PROSPECTS

92

ITEM 6.

DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES

107

ITEM 7.

MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

120

ITEM 8.

FINANCIAL INFORMATION

122

ITEM 9.

THE OFFER AND LISTING

123

ITEM 10.

ADDITIONAL INFORMATION

124

ITEM 11.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

136

ITEM 12.

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

136

 

 

 

PART II

138

 

 

 

ITEM 13.

DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES

138

ITEM 14.

MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS

138

ITEM 15.

CONTROLS AND PROCEDURES

138

ITEM 16A.

AUDIT COMMITTEE FINANCIAL EXPERT

139

ITEM 16B.

CODE OF ETHICS

139

ITEM 16C.

PRINCIPAL ACCOUNTANT FEES AND SERVICES

140

ITEM 16D.

EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES

140

ITEM 16E.

PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

140

ITEM 16F.

CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT

141

ITEM 16G.

CORPORATE GOVERNANCE

141

ITEM 16H.

MINE SAFETY DISCLOSURE

141

ITEM 16I.

DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

141

 

 

 

PART III

141

 

 

 

ITEM 17.

FINANCIAL STATEMENTS

141

ITEM 18.

FINANCIAL STATEMENTS

141

ITEM 19.

EXHIBITS

142

i

INTRODUCTION

Unless otherwise indicated and except where the context otherwise requires, in this annual report on Form 20-F:

“ADSs” refer to our American depositary shares, each of which represents four Class A ordinary shares;

“ADRs” refer to the American depositary receipts that evidence our ADSs;

“China” or the “PRC” refers to the People’s Republic of China, excluding, for the purpose of this annual report only, Hong Kong, Macau and Taiwan;

“Class A ordinary shares” refer to our class A ordinary shares, par value US$0.0001 per share;

“Class B ordinary shares” refer to our class B ordinary shares, par value US$0.0001 per share;

“Memorandum and Articles” refer to the second amended and restated memorandum of association and articles of association adopted by a special resolution passed on January 12, 2018 and effective on February 12, 2018;

“Mobile App MAUs” refer to monthly active users of our mobile apps, which are represented by the number of accounts that have been logged into on our mobile apps during a given calendar month. The numbers of our Mobile App MAUs are calculated using internal company data that have not been independently verified. It is possible that some users may have set up more than one account;

“ordinary shares” refer to our Class A and Class B ordinary shares, par value US$0.0001 per share;

“Our platform” refers to the products and mobile apps that we provide to users and platform partners;

“the VIEs” refer to Anhui Huami Information Technology Co., Ltd. and Huami (Beijing) Information Technology Co., Ltd., each of which is a company incorporated in the PRC;

“RMB” or “Renminbi” refers to the legal currency of China;

“Shunyuan Kaihua” or “our WFOE” refers to Beijing Shunyuan Kaihua Technology Co., Ltd., a wholly owned foreign enterprise incorporated with limited liability in the PRC;

“US$,” “U.S. dollars,” “$,” or “dollars” refer to the legal currency of the United States;

“Xiaomi” refers to Xiaomi Corporation;

“Xiaomi Wearable Products” refer to Xiaomi-branded smart bands, watches (excluding children watches and quartz watches), scales and associated accessories;

“Zepp,” “we,” “us,” “our company” or “our” refer to Zepp Health Corporation, our Cayman Islands holding company, and its subsidiaries, and, in the context of describing our operations and consolidated financial information, the VIEs in China, including Anhui Huami Information Technology Co., Ltd. and Huami (Beijing) Information Technology Co., Ltd., and their subsidiaries; and

“U.S. GAAP” refers to generally accepted accounting principles in the United States.

1

FORWARD-LOOKING STATEMENTS

This annual report on Form 20-F contains forward-looking statements that relate to our current expectations and views of future events. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigations Reform Act of 1995.

You can identify some of these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements include statements relating to:

our goals and strategies;

our future business development, financial conditions and results of operations;

the expected growth of the smart wearable devices industry;

our expectations regarding demand for and market acceptance of our products and services;

our expectations regarding our relationships Xiaomi, our other distributors, customers, contract manufacturers, component suppliers, strategic partners and other stakeholders;

regulatory and operating conditions in the geographical markets in which we operate;

competition in our industry; and

relevant government policies and regulations relating to our industry.

You should read this annual report and the documents that we refer to in this annual report and have filed as exhibits to this annual report completely and with the understanding that our actual future results may be materially different from what we expect. Other sections of this annual report discuss factors which could adversely impact our business and financial performance. Moreover, we operate in an evolving environment. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements.

You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this annual report relate only to events or information as of the date on which the statements are made in this annual report. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

Unless otherwise noted, all translations from Renminbi to U.S. dollars and from U.S. dollars to Renminbi in this annual report are made at a rate of RMB6.8972 to US$1.00, the exchange rate in effect as of December 30, 2022 as set forth in the H.10 statistical release of The Board of Governors of the Federal Reserve System. We make no representation that any Renminbi or U.S. dollar amounts could have been, or could be, converted into U.S. dollars or Renminbi, as the case may be, at any particular rate, or at all.

2

PART I

ITEM 1.              IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

Not applicable.

ITEM 2.              OFFER STATISTICS AND EXPECTED TIMETABLE

Not applicable.

ITEM 3.              KEY INFORMATION

Our Holding Company Structure and Contractual Arrangements with the VIEs

Zepp Health Corporation is not a Chinese operating company but a Cayman Islands holding company with no equity ownership in its consolidated variable interest entities, or VIEs. We conduct our operations in China through (i) our PRC subsidiaries and (ii) the VIEs with which we have maintained contractual arrangements and their subsidiaries in China. PRC laws and regulations impose certain restrictions or prohibitions on foreign ownership of companies that engage in developing substantial proprietary technology to produce consumer health and fitness devices. Accordingly, we operate these businesses in China through the VIEs and their subsidiaries, and rely on contractual arrangements among our PRC subsidiaries, the VIEs and their nominee shareholders to control the business operations of the VIEs. The VIEs are consolidated for accounting purposes, but are not entities in which our Cayman Islands holding company, or our investors, own equity. Revenues contributed by the VIEs accounted for 97.9%, 83.5% and 61.2% of our total revenues for the years ended December 31, 2020, 2021 and 2022, respectively. As used in this annual report, “Zepp,” “the Parent,” “we,” “us,” “our company” or “our” refers to Zepp Health Corporation, its subsidiaries, and, in the context of describing our consolidated financial information, the consolidated VIEs and their subsidiaries in China. “Consolidated VIEs” refer to Anhui Huami Information Technology Co., Ltd. and Huami (Beijing) Information Technology Co., Ltd., each of which is a company incorporated in the PRC. Investors in our ADSs thus are not purchasing equity interest in the consolidated VIEs in China but instead are purchasing equity interest in Zepp Health Corporation, a Cayman Islands holding company.

A series of contractual agreements, including loan agreement, equity pledge agreements, exclusive option agreements, exclusive consultation and service agreements, shareholder voting proxy agreements and powers of attorney, have been entered into by and among our subsidiaries, the VIEs and their respective shareholders. Terms contained in each set of contractual arrangements with the VIEs and their respective shareholders are substantially similar. As a result, despite the lack of equity ownership, Zepp Health Corporation is considered the primary beneficiary of the VIEs for accounting purposes as required by Accounting Standards Codification topic 810, Consolidation. Accordingly, we treat the VIEs as the consolidated entities under U.S. GAAP and we consolidate the financial results of the VIEs in our consolidated financial statements in accordance with U.S. GAAP. For more details of these contractual arrangements, see “Item 4. Information on the Company—C. Organizational Structure.”

However, the contractual arrangements may not be as effective as direct ownership in providing us with control over the VIEs and we may incur substantial costs to enforce the terms of the arrangements. Uncertainties in the PRC legal system may limit our ability, as a Cayman Islands holding company, to enforce these contractual arrangements. Meanwhile, the contractual arrangements with the VIEs and their respective shareholders have not been tested in a court of law. There are very few precedents as to whether contractual arrangements would be judged to form effective control over the relevant VIEs through the contractual arrangements, or how contractual arrangements in the context of a VIE should be interpreted or enforced by the PRC courts. Should legal actions become necessary, we cannot guarantee that the court will rule in favor of the enforceability of the VIE contractual arrangements. In the event we are unable to enforce these contractual arrangements, or if we suffer significant delay or other obstacles in the process of enforcing these contractual arrangements, we may not be able to exert effective control over the VIEs, and our ability to conduct our business may be materially adversely affected. See “Item 3. Key Information—D. Risk Factors—Risks Related to Our Corporate Structure—We rely on contractual arrangements with the VIEs and their shareholders for a large portion of our business operations, which may not be as effective as direct ownership in providing operational control” and “Item 3. Key Information—D. Risk Factors—Risks Related to Our Corporate Structure—The shareholders of the VIEs may have potential conflicts of interest with us, which may materially and adversely affect our business and financial condition.”

3

There are also substantial uncertainties regarding the interpretation and application of current and future PRC laws, regulations and rules regarding the status of the rights of our Cayman Islands holding company with respect to its contractual arrangements with the VIEs and their nominee shareholders. It is uncertain whether any new PRC laws or regulations relating to variable interest entity structures will be adopted or if adopted, what they would provide. If we or any of the VIEs is found to be in violation of any existing or future PRC laws or regulations, or fail to obtain or maintain any of the required permits or approvals, the relevant PRC regulatory authorities would have broad discretion to take action in dealing with such violations or failures. If the PRC government deems that our contractual arrangements with the VIEs do not comply with PRC regulatory restrictions on foreign investment in the relevant industries, or if these regulations or the interpretation of existing regulations change or are interpreted differently in the future, we could be subject to severe penalties or be forced to relinquish our interests in those operations. Our Cayman Islands holding company, our PRC subsidiaries and VIEs, and investors of our company face uncertainty about potential future actions by the PRC government that could affect the enforceability of the contractual arrangements with the VIEs and, consequently, significantly affect the financial performance of the VIEs and our company as a whole. The PRC regulatory authorities could disallow the VIE structure, which would likely result in a material adverse change in our operations, and our Class A ordinary shares or our ADSs may decline significantly in value or become worthless. As such, the VIE structure involves unique risks to our investors. See “Item 3. Key Information—D. Risk Factors—Risks Related to Our Corporate Structure—If the PRC government finds that the agreements that establish the structure for operating some of our operations in China do not comply with PRC regulations relating to the relevant industries, or if these regulations or the interpretation of existing regulations change in the future, we could be subject to severe penalties or be forced to relinquish our interests in those operations” and “—Our current corporate structure and business operations may be affected by the newly enacted Foreign Investment Law.”

We face various legal and operational risks and uncertainties associated with being based in or having our operations primarily in China and the complex and evolving PRC laws and regulations. For example, we face risks associated with the fact that the PRC government has significant authority in regulating our operations and may influence or intervene in our operations at any time, regulatory approvals or filing procedures on overseas offerings or listings by, and foreign investment in, China-based issuers, anti-monopoly regulatory actions, oversight on data security and the use of variable interest entities. In particular, the PRC regulatory and enforcement regime with regard to data security and data protection is evolving and may be subject to different interpretations or significant changes. Any failure to comply with applicable data security and privacy related regulations could result in regulatory enforcement actions against us, and the misuse of or failure to secure personal information could also result in violation of data privacy laws and regulations, proceedings against us by governmental entities or others, damage our reputation and credibility and could have a negative impact on our financial performance.

PRC government’s significant authority in regulating our operations and its oversight and control over overseas offerings and listings by, and foreign investment in, China-based issuers could significantly limit or completely hinder our ability to offer or continue to offer securities to investors. Implementation of industry-wide regulations in this nature may cause the value of such securities to significantly decline or become worthless. For more details, see “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—The PRC government’s significant oversight and discretion over our business operation could result in a material adverse change in our operations and the value of our ADSs.”

Risks and uncertainties arising from the legal system in China, including risks and uncertainties regarding the enforcement of laws and quickly evolving rules and regulations in China, could result in a material adverse change in our operations and the value of our ADSs. For more details, see “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—Uncertainties with respect to the PRC legal system and changes in laws and regulations in China could adversely affect us, and any lack of requisite approvals, licenses or permits applicable to our business may have a material adverse effect on our business and results of operations.”

4

The Holding Foreign Companies Accountable Act

Pursuant to the Holding Foreign Companies Accountable Act, or the HFCAA, if the SEC determines that we have filed audit reports issued by a registered public accounting firm that has not been subject to inspections by the PCAOB for two consecutive years, the SEC will prohibit our shares or the ADSs from being traded on a national securities exchange or in the over-the-counter trading market in the United States. On December 16, 2021, the PCAOB issued a report to notify the SEC of its determination that the PCAOB was unable to inspect or investigate completely registered public accounting firms headquartered in mainland China and Hong Kong, including our auditor. In May 2022, the SEC conclusively listed us as a Commission-Identified Issuer under the HFCAA following the filing of this annual report on Form 20-F for the fiscal year ended December 31, 2021. On December 15, 2022, the PCAOB issued a report that vacated its December 16, 2021 determination and removed mainland China and Hong Kong from the list of jurisdictions where it is unable to inspect or investigate completely registered public accounting firms. For this reason, we do not expect to be identified as a Commission-Identified Issuer under the HFCAA after we file this annual report on Form 20-F. Each year, the PCAOB will determine whether it can inspect and investigate completely audit firms in mainland China and Hong Kong, among other jurisdictions. If PCAOB determines in the future that it no longer has full access to inspect and investigate completely accounting firms in mainland China and Hong Kong and we continue to use an accounting firm headquartered in one of these jurisdictions to issue an audit report on our financial statements filed with the Securities and Exchange Commission, we would be identified as a Commission-Identified Issuer following the filing of the annual report on Form 20-F for the relevant fiscal year. There can be no assurance that we would not be identified as a Commission-Identified Issuer for any future fiscal year, and if we were so identified for two consecutive years, we would become subject to the prohibition on trading under the HFCAA. For more details, see “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—The PCAOB had historically been unable to inspect our auditor in relation to their audit work performed for our financial statements and the inability of the PCAOB to conduct inspections of our auditor in the past has deprived our investors with the benefits of such inspections.” and “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—Our ADSs may be prohibited from trading in the United States under the HFCAA in the future if the PCAOB is unable to inspect or investigate completely auditors located in China. The delisting of the ADSs, or the threat of their being delisted, may materially and adversely affect the value of your investment.”

Cash Flows through Our Organization

Zepp Health Corporation, our Cayman Islands holding company, or the Parent, may transfer cash to our wholly-owned Hong Kong subsidiary by making capital contributions or providing intra-group loans. Our Hong Kong subsidiary, in turn, may transfer cash to our PRC subsidiaries by making capital contributions or providing intra-group loans to them, provided that the statutory procedures under the PRC laws and regulations have been complied with. If our PRC subsidiaries realize accumulated after-tax profits, they may, upon satisfaction of relevant statutory conditions and procedures, pay dividends or distribute earnings to our Hong Kong Subsidiary. Our Hong Kong subsidiary, in turn, may transfer cash to the Parent through dividends or other distributions. With necessary funds, the Parent may pay dividends or make other distributions to U.S. investors and service any debt it may have incurred outside of the PRC. In addition, in the ordinary course of our business, Anhui Huami, one of the VIEs, sells our smart wearable products to Galaxy Trading Platform Limited, our intermediary company in Hong Kong, which in turn sells the products to overseas third parties. Anhui Huami also sells products to Zepp North America Inc. and Zepp Netherlands Trading B.V. through an independent customs clearance agency for the products to be distributed to local distributors and consumers in the U.S. and Europe, respectively. These entities settle payments of the smart wearable products in accordance with the specific transaction value and payment terms under the relevant contracts.

Because the Parent and its subsidiaries consolidate the financial results of the VIEs through contractual arrangements, they are not able to make direct capital contribution to the VIEs and its subsidiaries. However, they may transfer cash to the VIEs by loans or by making payment to the VIEs for intra-group transactions. The VIEs may transfer cash to our WFOEs by paying service fees according to the exclusive business cooperation agreements entered into by and among our WFOEs, the VIEs and their respective shareholders. Pursuant to these agreements between each of the VIEs and the corresponding WFOE, each of the VIEs agrees to pay the relevant WFOE (i) service fee at an amount that is equal to 100% of the net income of the VIE under local GAAP for the relevant year, which is subject to adjustments both upward and downward in accordance with the WFOE’s sole discretion, and (ii) service fee for certain other technical services provided to the VIE by the WFOE, the amount of which is to be mutually agreed between the VIE and the WFOE when such services are rendered, based on the nature and workload of such services. In the future, we plan to retain our sole discretion to determine the specific amount of the service fees payable by the VIEs pursuant to the contractual arrangements, and to obtain the earnings of the VIEs through charging service fees and collect the payments from the VIEs, taking into consideration of the business growth and working capital needs of the WFOEs and the VIEs. For details of the financial position, cash flows and results of operations of the VIEs, see “Financial Information Related to the VIEs.”

5

We have established stringent controls and procedures for cash flows within our organization. We have a centralized cash management system in place, consisting of a series of manuals and policies on funds management, bank accounts management, financing activities and safe handling of cash and assets. The system ensures that every fund transfer between our Cayman Islands holding company and a subsidiary, the VIEs or the subsidiaries of the VIEs goes through an appropriate review and approval process. The cash of our group is under the unified management of our finance department. Each cash requirement with intercompany transaction agreements, after analyzed by the specialist in the treasury department, is reviewed by the head of treasury department and the group finance controller. After such cash requirement is approved by the two responsible persons, the head of treasury department approves the cash transfer to the relevant operating entities. Besides, we have made offshore and onshore cash pooling arrangements with banks, which allow us to centralize our intra-group cash management across various subsidiaries. Account transfers are performed automatically between the accounts of the pool leader and the other pool participants, which are our operating entities. Our offshore entities outside of the mainland of China with the function of centralized cash management in offshore cash pooling arrangement mainly include Galaxy Trading Platform Ltd., our intermediate Hong Kong company acting as the pool leader, our subsidiaries in North America and our subsidiaries in Europe. In addition, entities within the mainland of China that participate in cash pooling arrangement with similar functions mainly include Shunyuan Kaihua (the WFOE and the primary beneficiary of the VIEs), Shanghai Shengyin Technology Co., Ltd. (a wholly-owned subsidiary of Shunyuan Kaihua) and Anhui Huami (a consolidated VIE). The centralized cash management function in these entities lead to daily cash transferred and dispatched to the remaining consolidated subsidiaries and consolidated VIEs. We have complied with the applicable laws and regulations for the operation of such cash centralized management accounts and completed necessary registration and approval procedures with relevant governmental authorities. The cash inflows of the Cayman Islands holding company were primarily generated from the proceeds we received from our public offerings of ordinary shares and other financing activities. The following table sets forth the amount of the transfers for the periods presented.

    

Years Ended December 31,

    

2020

    

2021

    

2022

(RMB in thousands)

Cash transferred from Hong Kong company to PRC subsidiaries, the VIEs and the subsidiaries of the VIEs

19,575

70,099

(40,544)

Net cash paid by the VIEs to our subsidiaries in operating activities

(605,423)

374,705

(486,252)

Net cash received/(paid) by the VIEs (to)/from our subsidiaries in investing activities

(597,614)

(290,767)

For more details, see the condensed consolidating schedule and consolidated financial statements under “Financial Information Related to the VIEs.” Except the transactions described above, for the years ended December 31, 2020, 2021 and 2022, no assets other than cash were transferred between the Cayman Islands holding company and a subsidiary or a VIE, no subsidiaries or VIE paid dividends or made other distributions to the holding company, and no dividends or distributions were paid or made to U.S. investors. Through the contractual arrangements, the VIEs may transfer cash to the WFOEs by paying service fees according to the exclusive business cooperation agreements entered into by and among the WFOEs, the VIEs and their respective shareholders. Pursuant to these agreements between each of the VIEs and the corresponding WFOE, each of the VIEs agrees to pay the relevant WFOE (i) service fee at an amount that is equal to 100% of the net income of the VIE under local GAAP for the relevant year, which is subject to adjustments both upward and downward in accordance with the WFOE’s sole discretion, and (ii) service fee for certain other technical services provided to the VIE by the WFOE. If and when such other technical services are provided, the amount to be charged is to be mutually agreed between the VIEs and the WFOEs based on the nature and workload of the services. Historically, the WFOE has not charged such service fees, and as such, there is currently no fees to be settled under the contractual arrangements. In April 2022, our Cayman Islands holding company declared and distributed cash dividends with the amount of approximately US$6.30 million to its shareholders and ADS holders, which was funded by surplus cash on our balance sheet. Other than the cash dividends paid in April 2022, we currently intend to retain our available funds and any future earnings to operate and expand our business.

6

As a Cayman Islands holding company, we may receive dividends from our PRC subsidiaries. Under the Enterprise Income Tax Law of the PRC, or the EIT Law, and its implementation rules, dividends generated after January 1, 2008 and payable by a foreign-invested enterprise in China to its foreign enterprise investors are subject to a 10% withholding tax, unless any such foreign investor’s jurisdiction of incorporation has a tax treaty with China that provides for a different withholding arrangement. Dividends paid by our wholly foreign-owned subsidiary in China to our intermediate holding company in Hong Kong will be subject to a withholding tax rate of 10%, unless the relevant Hong Kong entity satisfies all the requirements under the China-HK Taxation Arrangement. Effective from January 1, 2020, if our Hong Kong subsidiary satisfies all the requirements under such arrangement, the dividends paid to the Hong Kong subsidiary would be subject to withholding tax at the standard rate of 5%. It could obtain such entitlement by itself at the time of making tax returns, or at the time of making withholding declarations via withholding agents. At the same time, the Hong Kong entity shall collect, gather and retain relevant materials for future reference in accordance with applicable rules, and shall accept the follow-up administration of tax authorities. However, we cannot assure you that we will be able to enjoy the preferential withholding tax rate of 5% under the China-HK Taxation Arrangement. See “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—We may rely on dividends and other distributions on equity paid by our PRC subsidiaries to fund any cash and financing requirements we may have, and any limitation on the ability of our PRC subsidiaries to make payments to us could have a material and adverse effect on our ability to conduct our business” for more details. If our holding company in the Cayman Islands or any of our subsidiaries outside of China were deemed to be a “resident enterprise” under the PRC Enterprise Income Tax Law, it would be subject to enterprise income tax on its worldwide income at a rate of 25%. See “Risk Factors—If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to us and our non-PRC shareholders or ADS holders.”

For purposes of illustration, the following discussion reflects the hypothetical taxes that might be required to be paid within China, assuming that: (i) we have taxable earnings, and (ii) we determine to pay dividends in the future.

    

Tax calculation(1)

 

Hypothetical pre-tax earnings(2)

 

100

%

Tax on earnings at statutory rate of 25%(3)

(25)

%

Net earnings available for distribution

 

75

%

Withholding tax at standard rate of 10%(4)

(7.5)

%

Net distribution to Parent/Shareholders

 

67.5

%

Notes:

(1)

For purposes of this example, the tax calculation has been simplified. The hypothetical book pre-tax earnings amount, not considering timing differences, is assumed to equal taxable income in China.

(2)

Under the terms of VIE agreements, our WFOE may charge the VIEs for services provided to VIEs. These service fees shall be recognized as expenses of the VIEs, with a corresponding amount as service income by our WFOE and eliminate in consolidation. For income tax purposes, our WFOE and VIEs file income tax returns on a separate company basis. The service fees paid are recognized as a tax deduction by the VIEs and as income by our WFOE and are tax neutral.

(3)

Certain of our subsidiaries and VIEs qualify for a 15% preferential income tax rate in China. However, such rate is subject to qualification, is temporary in nature, and may not be available in a future period when distributions are paid. For purposes of this hypothetical example, the table above reflects a maximum tax scenario under which the full statutory rate would be effective.

(4)

The PRC Enterprise Income Tax Law imposes a withholding income tax of 10% on dividends distributed by a foreign invested enterprise, or FIE, to its immediate holding company outside of China. A lower withholding income tax rate of 5% is applied if the FIE’s immediate holding company is registered in Hong Kong or other jurisdictions that have a tax treaty arrangement with China, subject to a qualification review at the time of the distribution. For purposes of this hypothetical example, the table above assumes a maximum tax scenario under which the full withholding tax would be applied.

7

The table above has been prepared under the assumption that all profits of the VIEs will be distributed as fees to our WFOE under tax neutral contractual arrangements. If, in the future, the accumulated earnings of the VIEs exceed the service fees paid to our WFOE (or if the current and contemplated fee structure between the intercompany entities is determined to be non-substantive and disallowed by Chinese tax authorities), the VIEs could make a non-deductible transfer to our WFOE for the amounts of the stranded cash in the VIEs. This would result in such transfer being non-deductible expenses for the VIEs but still taxable income for our WFOE. Such a transfer and the related tax burdens would reduce our after-tax income to approximately 50.6% of the pre-tax income. Our management believes that there is only a remote possibility that this scenario would happen.

Under PRC laws and regulations, we are subject to restrictions on foreign exchange and cross-border cash transfers, including to U.S. investors. Our ability to distribute earnings to the holding company and U.S. investors is also limited. We are a Cayman Islands holding company and we may rely on dividends and other distributions on equity paid by our PRC subsidiary, which in turn relies on consulting and other fees paid to us by the VIEs, for our cash and financing requirements, including the funds necessary to pay dividends and other cash distributions to our shareholders and service any debt we may incur. When any of our PRC subsidiary incurs debt on its own behalf, the instruments governing the debt may restrict its ability to pay dividends or make other distributions to us.

Our subsidiaries’ ability to distribute dividends is based upon their distributable earnings. Current PRC regulations permit our PRC subsidiaries to pay dividends to their respective shareholders only out of their accumulated profits, if any, determined in accordance with PRC accounting standards and regulations. In addition, each of our PRC subsidiaries and the VIEs and their subsidiaries is required to set aside at least 10% of its after-tax profits each year, if any, to fund a statutory reserve until such reserve reaches 50% of its registered capital. Each of such entities in China is also required to further set aside a portion of its after-tax profits to fund the employee welfare fund, although the amount to be set aside, if any, is determined at the discretion of its board of directors. These reserves are not distributable as cash dividends.

In addition, our PRC subsidiaries, the VIEs and their subsidiaries generate their revenue primarily in Renminbi, which is not freely convertible into other currencies. As a result, any restriction on currency exchange may limit the ability of our PRC subsidiaries to pay dividends to us. For more details, see “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from using the proceeds of our initial public offering and our ADS offering in April 2019 to make loans or additional capital contributions to our PRC subsidiaries, which could materially and adversely affect our liquidity and our ability to fund and expand our business.”

Permissions Required from the PRC Authorities for Our Operations

We conduct our business primarily through our subsidiaries and VIEs in China. Our operations in China are governed by PRC laws and regulations. As of the date of this annual report, our PRC subsidiaries, VIEs and their subsidiaries have obtained the requisite licenses and permits from the PRC government authorities that are material for the business operations of our holding company, the VIEs in China, including, among others, the Business License, the ICP License, the Insurance Brokerage License, etc. Given the uncertainties of interpretation and implementation of relevant laws and regulations and the enforcement practice by relevant government authorities, we may be required to obtain additional licenses, permits, filings or approvals for the functions and services of our platform in the future. Any failure to obtain or delay in obtaining such permissions or approvals, or a rescission of any such approval if obtained by us, would subject us to sanctions by the applicable PRC regulatory authorities. These regulatory authorities may impose fines and penalties on our operations in China, limit our ability to pay dividends outside of China, limit our operating privileges in China, delay or restrict the repatriation of the proceeds from our offshore offerings into China or take other actions that could materially and adversely affect our business, financial condition, results of operations, and prospects, as well as the trading price of our ADSs. For more detailed information, see “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—Uncertainties with respect to the PRC legal system and changes in laws and regulations in China could adversely affect us, and any lack of requisite approvals, licenses or permits applicable to our business may have a material adverse effect on our business and results of operations.”

8

Furthermore, in connection with offering and listing in an overseas market, we, our PRC subsidiaries and the VIEs, under the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (the “Trial Measures”) as well as five supporting guidelines, released by the China Securities Regulatory Commission, or the CSRC, on February 17, 2023, and took effect on March 31, 2023, may be required to fulfill filing procedures with and report material events to the CSRC, and under the Measures for Cybersecurity Review, which is effective on February 15, 2022, as well as its relevant laws, regulations and regulatory rules, may be required to go through cybersecurity review by the Cyberspace Administration of China, or the CAC. As of the date of this annual report, we have not received or were denied such requisite approval by the CSRC, nor have we been subject to any cybersecurity review made by the CAC. If we fail to obtain the relevant approval or complete other filing procedures, we may face sanctions by the CSRC or other PRC regulatory authorities, which may include fines and penalties on our operations in China, limitations on our operating privileges in China, restrictions on or prohibition of the payments or remittance of dividends by our subsidiaries in China, or other actions that could have a material and adverse effect on our business, financial condition, results of operations, reputation and prospects, as well as the trading price of our ADSs. If we had inadvertently concluded that such approvals were not required, or if applicable laws, regulations or interpretations change in a way that requires us to obtain such approval in the future, we may be unable to obtain such necessary approvals in a timely manner, or at all, and such approvals may be rescinded even if obtained. Any such circumstance could subject us to penalties, including fines, suspension of business and revocation of required licenses, significantly limit or completely hinder our ability to continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless. For more detailed information, see “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—The filing with and/or approval of the CSRC or other PRC government authorities may be required in connection with our offshore offerings under PRC law, and, if required, we cannot predict whether or for how long we will be able to complete such filing or obtain such approval” and “—We collect, store, process and use personal information and other user data, which subjects us to laws, governmental regulations and other legal obligations related to privacy, information security and data protection, and any actual or perceived failure to comply with such legal obligations could harm our brand and business.”

A.

Selected Financial Data

Our Selected Consolidated Financial Data

The following selected consolidated statements of operating data for the years ended December 31, 2020, 2021 and 2022, selected consolidated balance sheet data as of December 31, 2021 and 2022 and selected consolidated cash flow data for the years ended December 31, 2020, 2021 and 2022 have been derived from our audited consolidated financial statements included elsewhere in this annual report. The selected consolidated statements of operating data for the years ended December 31, 2018 and 2019, the selected consolidated balance sheet data as of December 31, 2018, 2019 and 2020 and selected consolidated cash flow data for the years ended December 31, 2018 and 2019 have been derived from our audited consolidated financial statements that are not included in this annual report. Our consolidated financial statements are prepared and presented in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP.

9

You should read the selected consolidated financial information in conjunction with our consolidated financial statements and related notes and “Item 5. Operating and Financial Review and Prospects” included elsewhere in this annual report. Our historical results are not necessarily indicative of our results expected for future periods.

Years Ended December 31,

2018

2019

2020

2021

2022

    

RMB

    

RMB

    

RMB

    

RMB

    

RMB

    

US$

(in thousands, except for per share data)

Selected Consolidated Statements of Operating Data:

  

  

  

  

  

  

Revenues(1)

 

3,645,335

 

5,812,255

 

6,433,363

 

6,250,109

 

4,142,862

 

600,659

Cost of revenues(2)

 

2,705,885

 

4,344,512

 

5,100,698

 

4,944,467

 

3,339,746

 

484,218

Gross profit

 

939,450

 

1,467,743

 

1,332,665

 

1,305,642

 

803,116

 

116,441

Operating expenses:

 

 

 

 

 

 

Research and development(3)

 

263,220

 

430,822

 

538,009

 

515,081

 

517,122

 

74,976

General and administrative(3)

 

213,973

 

248,462

 

261,805

 

258,346

 

235,932

 

34,207

Selling and marketing(3)

 

96,538

 

181,975

 

358,655

 

438,273

 

460,304

 

66,738

Total operating expenses

 

573,731

 

861,259

 

1,158,469

 

1,211,700

 

1,213,358

 

175,921

Operating income/(loss)

 

365,719

 

606,484

 

174,196

 

93,942

 

(410,242)

 

(59,480)

Other income and expenses:

 

 

 

 

 

 

Realized gain from investments

 

261

 

1,822

 

 

13,507

 

597

 

87

Gain from deconsolidation of a subsidiary

56,522

Interest income

 

11,595

 

33,478

 

46,118

 

16,686

 

12,334

 

1,788

Interest expense

(22,623)

(44,884)

(57,001)

(8,264)

Gain from fair value change of long-term investments

 

7,860

 

 

12,325

 

 

51,817

 

7,513

Impairment loss from long-term investments

 

(7,590)

 

(2,600)

 

 

 

(13,858)

 

(2,009)

Other income/(loss), net

 

8,768

 

13,186

 

(929)

 

27,418

 

43,820

 

6,353

Income/(Loss) before income tax

 

386,613

 

652,370

 

265,609

 

106,669

 

(372,533)

 

(54,012)

Income taxes (provision)/benefit

 

(52,036)

 

(77,887)

 

(31,154)

 

(10,745)

 

65,875

 

9,551

Income/(Loss) before income/(loss) from equity method investments

 

334,577

 

574,483

 

234,455

 

95,924

 

(306,658)

 

(44,461)

Income/(loss) from equity method investments

 

1,743

 

(1,112)

 

(4,749)

 

41,028

 

17,657

 

2,560

Net income/(loss)

 

336,320

 

573,371

 

229,706

 

136,952

 

(289,001)

 

(41,901)

Less: net (loss)/income attributable to non-controlling interest

 

(3,726)

 

(1,825)

 

953

 

(851)

 

(693)

 

(100)

Net income attributable to Zepp Health Corporation

 

340,046

 

575,196

 

228,753

 

137,803

 

(288,308)

 

(41,801)

Net income per share attributable to ordinary shareholders of Zepp Health Corporation:

 

 

 

 

 

 

Basic income/(loss) per ordinary share

 

0.54

 

2.35

 

0.92

 

0.55

 

(1.17)

 

(0.17)

Diluted income/(loss) per ordinary share

 

0.51

 

2.24

 

0.88

 

0.52

 

(1.17)

 

(0.17)

Notes:

(1)

Includes RMB2,817.0 million, RMB4,281.0 million, RMB4,449.8 million, RMB3,350.0 million and RMB1,704.0 million (US$247.1 million) with related parties for the years ended December 31, 2018, 2019, 2020, 2021 and 2022, respectively.

(2)

Includes RMB2,141.1 million, RMB3,342.1 million, RMB3,713.5 million, RMB2,760.0 million and RMB1,399.5 million (US$202.9 million) resulting from related parties sales for the years ended December 31, 2018, 2019, 2020, 2021 and 2022, respectively.

10

(3)Share-based compensation expenses were included in operating expenses. Our share-based compensation expenses were the result of our grants of options, restricted shares and restricted share units under our share incentive plans to our employees.

The following table presents our selected consolidated balance sheet data as of the dates indicated.

As of December 31,

2018

2019

2020

2021

2022

    

RMB

    

RMB

    

RMB

    

RMB

    

RMB

    

US$

(in thousands)

Selected Consolidated Balance Sheet Data:

  

  

  

  

  

  

Current assets:

 

  

 

  

 

  

 

  

 

  

 

  

Cash and cash equivalents

 

1,441,802

 

1,803,117

 

2,273,349

 

1,468,499

 

886,632

 

128,550

Restricted cash

10,010

874

2,401

41,040

86,708

12,571

Accounts receivable (net of allowance of nil, RMB814 and RMB1,466 as of December 31, 2020, 2021 and 2022, respectively)

 

58,925

 

188,940

 

298,038

 

537,084

 

682,103

 

98,896

Amount due from related parties (net of allowance of nil, nil and nil as of December 31, 2020, 2021 and 2022, respectively)

 

656,399

 

1,421,170

 

860,213

 

295,614

 

138,614

 

20,097

Inventories

 

484,622

 

893,806

 

1,217,537

 

1,249,327

 

1,021,923

 

148,165

Total current assets

2,857,456

4,392,452

4,827,866

3,930,953

2,958,548

428,948

Non-current assets:

 

 

 

 

 

 

Property, plant and equipment, net

 

40,042

 

64,350

 

124,619

 

133,873

 

100,605

 

14,586

Total assets

 

3,258,481

 

5,174,743

 

5,903,719

 

6,085,501

 

5,267,643

 

763,735

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

1,064,106

 

1,999,951

 

1,951,335

 

1,317,306

 

456,585

 

66,198

Short-term bank borrowings

 

20,000

 

 

504,671

 

358,000

 

512,000

 

74,233

Total liabilities

 

1,448,903

 

2,677,155

 

3,173,461

 

3,152,062

 

2,582,722

 

374,459

Total liabilities and equity

 

3,258,481

 

5,174,743

 

5,903,719

 

6,085,501

 

5,267,643

 

763,735

The following table presents our selected cash flows for the years indicated.

Years Ended December 31,

2018

2019

2020

2021

2022

    

RMB

    

RMB

    

RMB

    

RMB

    

RMB

    

US$

(in thousands)

Selected Consolidated Cash Flow Data:

 

  

 

  

 

  

 

  

 

  

 

  

Net cash provided by/(used in) operating activities

 

707,605

 

427,999

 

157,302

 

(232,435)

 

(787,643)

 

(114,199)

Net cash used in investing activities

 

(324,841)

 

(112,703)

 

(206,880)

 

(1,069,289)

 

(42,258)

 

(6,127)

Net cash provided by financing activities

 

639,170

 

25,609

 

564,671

 

551,077

 

289,198

 

41,928

Net increase/(decrease) in cash and cash equivalents and restricted cash

 

1,021,934

 

340,905

 

515,093

 

(750,647)

 

(540,703)

 

(78,398)

Exchange rate effect on cash and cash equivalents and restricted cash

 

60,357

 

11,274

 

(43,334)

 

(15,564)

 

4,504

 

656

Cash and cash equivalents and restricted cash at the beginning of the year

 

369,521

 

1,451,812

 

1,803,991

 

2,275,750

 

1,509,539

 

218,863

Cash and cash equivalents and restricted cash at end of the year

 

1,451,812

 

1,803,991

 

2,275,750

 

1,509,539

 

973,340

 

141,121

11

Financial Information Related to the VIEs

The following table presents the condensed consolidating schedule of financial position for the VIEs and other entities as of the dates presented. In the following tables, “Primary Beneficiary of VIEs” refers to Beijing Shunyuan Kaihua Technology Co., Ltd., our WFOE who entered into contractual arrangements with the VIEs and their respective shareholders and acts as the primary beneficiary under the contractual arrangements. “Other Subsidiaries” refer to the subsidiaries of Zepp Health Corporation, our Cayman holding company, other than Beijing Shunyuan Kaihua Technology Co., Ltd., the VIEs and the subsidiaries of the VIEs.

Selected Condensed Consolidating Statements of Operations Data

For the Year Ended December 31, 2022

Primary

VIEs and

Zepp Health

Other

Beneficiary of

VIEs’

Eliminating

Consolidated

    

Corporation

    

Subsidiaries

    

VIEs

    

Subsidiaries

    

adjustments

    

Totals

(RMB, in thousands)

Third-party revenues

 

 

1,605,999

 

 

2,536,863

 

 

4,142,862

Inter-company revenues

 

 

376,730

 

100,101

 

1,514,863

 

(1,991,694)

 

Total revenues

 

 

1,982,729

 

100,101

 

4,051,726

 

(1,991,694)

 

4,142,862

Total cost and expenses

 

(56,813)

 

(2,123,058)

 

(225,010)

 

(4,182,082)

 

2,033,859

 

(4,553,104)

Income/(loss) from subsidiaries and VIEs

(231,495)

 

(162,902)

 

(66,341)

 

 

460,738

 

Other income and expense

 

 

3,304

 

4,867

 

29,538

 

 

37,709

Income/(loss) before income tax expenses

 

(288,308)

 

(299,927)

 

(186,383)

 

(100,818)

 

502,903

 

(372,533)

Income tax benefits/(provision)

 

 

20,258

 

23,481

 

25,063

 

(2,927)

 

65,875

Income/(loss) before loss from equity method investments

 

(288,308)

 

(279,669)

 

(162,902)

 

(75,755)

 

499,976

 

(306,658)

Income from equity method investments

 

 

8,243

 

 

9,414

 

 

17,657

Net income/(loss)

 

(288,308)

 

(271,426)

 

(162,902)

 

(66,341)

 

499,976

 

(289,001)

Net loss attributable to non-controlling interests

 

 

693

 

 

 

 

693

Net income/(loss) attributable to Zepp Health Corporation’s shareholders

 

(288,308)

 

(270,733)

 

(162,902)

 

(66,341)

 

499,976

 

(288,308)

For the Year Ended December 31, 2021

Primary

VIEs and

Zepp Health

Other

Beneficiary of

VIEs’

Eliminating

Consolidated

    

Corporation

    

Subsidiaries

    

VIEs

    

Subsidiaries

    

adjustments

    

Totals

(RMB, in thousands)

Third-party revenues

1,030,549

5,219,560

6,250,109

Inter-company revenues

 

 

533,943

 

240,103

 

1,202,152

 

(1,976,198)

 

Total revenues

 

 

1,564,492

 

240,103

 

6,421,712

 

(1,976,198)

 

6,250,109

Total costs and expenses

 

(94,824)

 

(1,561,349)

 

(240,920)

 

(6,063,153)

 

1,804,079

 

(6,156,167)

Income/(loss) from subsidiaries and VIEs

 

232,566

 

378,511

 

384,365

 

 

(995,442)

 

Income/(loss) from non-operations

 

61

 

1,174

 

(10)

 

34,728

 

(23,226)

 

12,727

Income/(loss) before income tax expenses

 

137,803

 

382,828

 

383,538

 

393,287

 

(1,190,787)

 

106,669

Income tax benefits/(provision)

 

 

8,501

 

(5,027)

 

(42,509)

 

28,290

 

(10,745)

Income/(loss) before loss from equity method investments

 

137,803

 

391,329

 

378,511

 

350,778

 

(1,162,497)

 

95,924

Income from equity method investments

 

 

7,441

 

 

33,587

 

 

41,028

Net income/(loss)(1)

 

137,803

 

398,770

 

378,511

 

384,365

 

(1,162,497)

 

136,952

Net loss attributable to non-controlling interests

 

 

851

 

 

 

 

851

Net income/(loss) attributable to Zepp Health Corporation’s shareholders

 

137,803

 

399,621

 

378,511

 

384,365

 

(1,162,497)

 

137,803

Note:

12

(1)The net income includes gain from inter-company transactions where the VIEs sold out products through our other subsidiaries functioning as international distributors of the group.

For the Year Ended December 31, 2020

Primary

VIEs and

Zepp Health

Other

Beneficiary of

VIEs’

Eliminating

Consolidated

    

Corporation

    

Subsidiaries

    

VIEs

    

Subsidiaries

    

adjustments

    

Totals

(RMB, in thousands)

Third-party revenues

132,682

3,147

6,297,534

6,433,363

Inter-company revenues

 

 

285,645

 

147,237

 

184,619

 

(617,501)

 

Total revenues

 

418,327

 

150,384

 

6,482,153

 

(617,501)

 

6,433,363

Total cost and expenses

(81,162)

 

(530,557)

 

(215,859)

 

(6,007,145)

 

575,556

 

(6,259,167)

Income/(loss) from subsidiaries and VIEs

308,578

 

427,093

 

490,493

 

 

(1,226,164)

 

Income from non-operations

1,337

 

13,060

 

492

 

53,351

 

23,173

 

91,413

Income/(loss) before income tax expenses

228,753

 

327,923

 

425,510

 

528,359

 

(1,244,936)

 

265,609

Income tax benefit/(provision)

 

6,739

 

1,583

 

(39,476)

 

 

(31,154)

Income/(loss) before loss from equity method investments

228,753

 

334,662

 

427,093

 

488,883

 

(1,244,936)

 

234,455

(Loss)/income from equity method investments

 

(7,312)

 

 

2,563

 

 

(4,749)

Net income /(loss)

228,753

 

327,350

 

427,093

 

491,446

 

(1,244,936)

 

229,706

Net income attributable to non-controlling interests

 

 

 

(953)

 

 

(953)

Net income/(loss) attributable to Zepp Health Corporation’s shareholders

228,753

 

327,350

 

427,093

 

490,493

 

(1,244,936)

 

228,753

13

Selected Condensed Consolidating Balance Sheets Data

As of December 31, 2022

Primary

VIEs and

Zepp Health

Other

Beneficiary of

VIEs’

Eliminating

Consolidated

    

Corporation

    

Subsidiaries

    

VIEs

    

Subsidiaries

    

adjustments

    

Totals

(RMB, in thousands)

Assets

  

  

  

  

  

  

Cash and cash equivalents

3,818

149,758

119,072

613,984

886,632

Restricted cash

 

620

 

 

86,088

 

 

86,708

Accounts receivable, net

 

304,275

 

3,217

 

374,611

 

 

682,103

Amount due from related parties

 

1,217

 

 

137,397

 

 

138,614

Inventories, net

294,518

735,600

(8,195)

1,021,923

Short-term investments

 

7,198

 

 

27,118

 

 

34,316

Prepaid expenses and other current assets

3,369

 

28,993

 

5,079

 

70,811

 

 

108,252

Intra-group receivable due from Zepp Health Corporation’s subsidiaries

850,623

 

1,045,050

 

201,527

 

1,916,093

 

(4,013,293)

 

Total current assets

857,810

 

1,831,629

 

328,895

 

3,961,702

 

(4,021,488)

 

2,958,548

Property, plant and equipment, net

 

12,045

 

6,190

 

82,370

 

-

 

100,605

Intangible assets, net

 

162,315

 

65,072

 

65,004

 

(169,091)

 

123,300

Long-term investments

 

1,230,599

 

 

456,029

 

 

1,686,628

Investment in subsidiaries and VIEs

1,914,207

 

447,195

 

338,024

 

 

(2,699,426)

 

Deferred tax assets

 

56,702

 

42,326

 

85,794

 

25,364

 

210,186

Amount due from a related party, non-current

6,333

6,333

Operating lease right-of-use assets

 

35,496

 

2,909

 

27,168

 

 

65,573

Goodwill

 

66,081

 

 

 

 

66,081

Other non-current assets

 

5,154

 

839

 

44,396

 

 

50,389

Intra-Group noncurrent receivable due to the Company's subsidiaries

377,084

(377,084)

Total non-current assets

1,914,207

2,021,920

455,360

1,137,845

(3,220,237)

2,309,095

Total assets

 

2,772,017

 

3,853,549

 

784,255

 

5,099,547

 

(7,241,725)

 

5,267,643

Liabilities

 

 

 

 

 

 

Accounts payable

 

4,411

 

135

 

452,039

 

 

456,585

Advance from customers

 

 

 

2,133

 

 

2,133

Amount due to related parties

 

 

2,065

 

38,913

 

 

40,978

Accrued expenses and other current liabilities

178

 

67,526

 

10,238

 

119,877

 

 

197,819

Intra-group payable due to Zepp Health Corporation’s subsidiaries

99,317

 

2,694,203

 

496,314

 

729,201

 

(4,019,035)

 

Income tax payables

 

2,308

 

 

407

 

 

2,715

Notes payable

 

 

 

456,438

 

 

456,438

Short-term bank borrowings

 

60,000

 

 

452,000

 

 

512,000

Total current liabilities

99,495

 

2,828,448

 

508,752

 

2,251,008

 

(4,019,035)

 

1,668,668

Deferred tax liabilities

3,159

32,393

35,552

Long-term borrowings

 

415,000

 

 

280,000

 

(10,790)

 

684,210

Other non-current liabilities

 

775

 

 

161,827

 

 

162,602

Intra-Group noncurrent payable due to the Company's subsidiaries

366,293

(366,293)

Non-current operating lease liabilities

 

21,414

 

 

10,276

 

 

31,690

Total non-current liabilities

806,641

484,496

(377,083)

914,054

Total liabilities

 

99,495

 

3,635,089

 

508,752

 

2,735,504

 

(4,396,118)

 

2,582,722

Total equity

 

2,672,522

 

218,460

 

275,503

 

2,364,043

 

(2,845,607)

 

2,684,921

Total liabilities and equity

 

2,772,017

 

3,853,549

 

784,255

 

5,099,547

 

(7,241,725)

 

5,267,643

14

As of December 31, 2021

Primary

VIEs and

Zepp Health

Other

Beneficiary of

VIEs’

Eliminating

Consolidated

    

Corporation

    

Subsidiaries

    

VIEs

    

Subsidiaries

    

adjustments

    

Totals

(RMB, in thousands)

Assets

  

  

  

  

  

  

Cash and cash equivalents

19,634

464,638

30,809

953,418

1,468,499

Restricted cash

 

 

572

 

 

40,468

 

 

41,040

Term deposit

 

 

 

 

5,000

 

 

5,000

Accounts receivable, net

 

 

185,699

 

4,360

 

347,025

 

 

537,084

Amount due from related parties

 

 

 

322

 

295,292

 

 

295,614

Inventories, net

 

 

242,441

 

1,036,617

(29,731)

 

1,249,327

Short-term investments

 

 

 

 

19,351

 

 

19,351

Prepaid expenses and other current assets

 

3,010

 

16,804

 

2,921

 

292,303

 

 

315,038

Intra-group receivable due from Zepp Health Corporation’s subsidiaries

801,856

886,839

233,540

1,779,374

(3,701,609)

Total current assets

 

824,500

 

1,796,993

 

271,952

 

4,768,848

 

(3,731,340)

 

3,930,953

Property, plant and equipment, net

 

 

16,592

 

11,021

 

106,260

 

 

133,873

Intangible assets, net

 

 

183,580

 

73,251

 

67,353

 

(188,602)

 

135,582

Long-term investments

 

 

1,380,141

 

20,000

 

386,635

 

(234,185)

 

1,552,591

Investment in subsidiaries and VIEs

 

2,128,912

 

378,512

 

384,365

 

 

(2,891,789)

 

Deferred tax assets

 

 

36,017

 

18,847

 

60,265

 

28,290

 

143,419

Operating lease right-of-use assets

 

 

50,593

 

15,904

 

41,938

 

 

108,435

Goodwill

 

 

61,055

 

 

 

 

61,055

Other non-current assets

 

 

5,882

 

4,294